▲ 1.10%
prev close
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
-1
0 buys · 1 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-09-25 | DVADaVita Inc. Common Stock | Sell | $1,001 - $15,000 | 239d ago | — |
2025-09-25
Julie Johnson
DVA
Amount
$1,001 - $15,000
Filed
239d ago
Recent News
Powered by Polygon.io
S&P 500, Nasdaq 100 Smash Records As AMD Jumps 16% On AI Hype: Stock Market Today
Heart Risks Go Beyond the Heart: Don’t Forget to Check Blood Sugar and Kidney Health
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
3 No-Brainer Warren Buffett Stocks to Buy Right Now
2 Warren Buffett Stocks to Buy Hand Over Fist This Month, and 1 to Avoid
Trade Timeline
Congressional activity, newest first
Julie Johnson
2025-09-25 · Sale
$1,001 - $15,000